Nivolumab for treating advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA384
  • Published: 
Download guidance (PDF)

6 Review of guidance

6.1 The guidance on this technology will be considered for review 2 years after publication along with guidance on other immunotherapies for advanced melanoma (such as technology appraisal guidance 268, 319, 357 and 366). The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
February 2016